207 related articles for article (PubMed ID: 30562193)
1. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
3. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
4. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
5. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
6. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
7. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
8. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
9.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
10. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
11. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
13. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of
Saponjski J; Macut D; Saranovic DS; Radovic B; Artiko V
Radiol Oncol; 2020 Nov; 55(1):18-25. PubMed ID: 33885241
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
[TBL] [Abstract][Full Text] [Related]
16. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
17. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on the clinical relevance of
Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
